Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30701% above fair value
$47.00−1.30 (-2.69%)
Close on Nov 20, 2026Market cap $4.43BP/E –Yield –
Travere Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Travere Therapeutics's net income for the twelve months ending Jun 30, 2026 was -$43.46M. For fiscal 2026 it was -$25.55M. The highest annual figure on record is $117.24M in fiscal 2016.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | -$25.55M | – |
| FY2025 | Dec 31, 2024 | -$321.55M | – |
| FY2024 | Dec 31, 2023 | -$111.40M | – |
| FY2023 | Dec 31, 2022 | -$278.48M | – |
| FY2022 | Dec 31, 2021 | -$180.09M | – |
| FY2021 | Dec 31, 2020 | -$169.43M | – |
| FY2020 | Dec 31, 2019 | -$146.43M | – |
| FY2019 | Dec 31, 2018 | -$102.68M | – |
| FY2018 | Dec 31, 2017 | -$59.73M | – |
| FY2017 | Dec 31, 2016 | -$47.90M | -140.9% |
| FY2016 | Dec 31, 2015 | $117.24M | – |
| FY2015 | Dec 31, 2014 | -$110.94M | – |
| FY2014 | Dec 31, 2013 | -$34.63M | – |
| FY2012 | Feb 29, 2012 | -$14.83K | – |
| FY2011 | Feb 28, 2011 | -$23.02K | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | -$34.80M | – |
| Q1 FY2027 | Mar 31, 2026 | -$37.10M | – |
| Q4 FY2026 | Dec 31, 2025 | $2.73M | – |
| Q3 FY2026 | Sep 30, 2025 | $25.71M | – |
| Q2 FY2026 | Jun 30, 2025 | -$12.76M | – |
| Q1 FY2026 | Mar 31, 2025 | -$41.23M | – |
| Q4 FY2025 | Dec 31, 2024 | -$60.26M | – |
| Q3 FY2025 | Sep 30, 2024 | -$54.81M | -136.4% |
| Q2 FY2025 | Jun 30, 2024 | -$70.41M | – |
| Q1 FY2025 | Mar 31, 2024 | -$136.06M | – |
| Q4 FY2024 | Dec 31, 2023 | -$90.17M | – |
| Q3 FY2024 | Sep 30, 2023 | $150.74M | – |
| Q2 FY2024 | Jun 30, 2023 | -$85.63M | – |
| Q1 FY2024 | Mar 31, 2023 | -$86.33M | – |
| Q4 FY2023 | Dec 31, 2022 | -$65.82M | – |
| Q3 FY2023 | Sep 30, 2022 | -$69.66M | – |
| Q2 FY2023 | Jun 30, 2022 | -$67.03M | – |
| Q1 FY2023 | Mar 31, 2022 | -$75.97M | – |
| Q4 FY2022 | Dec 31, 2021 | -$51.57M | – |
| Q3 FY2022 | Sep 30, 2021 | -$35.64M | – |
| Q2 FY2022 | Jun 30, 2021 | -$39.01M | – |
| Q1 FY2022 | Mar 31, 2021 | -$53.87M | -6766.7% |
| Q4 FY2021 | Dec 31, 2020 | -$121.62M | – |
| Q3 FY2021 | Sep 30, 2020 | -$22.55M | – |
| Q2 FY2021 | Jun 30, 2020 | -$26.07M | – |
| Q1 FY2021 | Mar 31, 2020 | $808.00K | – |
| Q4 FY2020 | Dec 31, 2019 | -$30.26M | – |
| Q3 FY2020 | Sep 30, 2019 | -$36.49M | – |
| Q2 FY2020 | Jun 30, 2019 | -$38.70M | – |
| Q1 FY2020 | Mar 31, 2019 | -$40.98M | – |
| Q4 FY2019 | Dec 31, 2018 | -$7.46M | – |
| Q3 FY2019 | Sep 30, 2018 | -$54.52M | – |
| Q2 FY2019 | Jun 30, 2018 | -$22.33M | – |
| Q1 FY2019 | Mar 31, 2018 | -$18.38M | – |
| Q4 FY2018 | Dec 31, 2017 | -$17.62M | – |
| Q3 FY2018 | Sep 30, 2017 | -$17.79M | – |
| Q2 FY2018 | Jun 30, 2017 | -$13.23M | – |
| Q1 FY2018 | Mar 31, 2017 | -$11.09M | – |
| Q4 FY2017 | Dec 31, 2016 | -$8.60M | – |
| Q3 FY2017 | Sep 30, 2016 | -$37.11M | – |
See a number that looks wrong?